[Skip to Content]
[Skip to Content Landing]
February 28, 1966

Irregular Menses, Amenorrhea, and Infertility Following Synthetic Progestational Agents

Author Affiliations

From the departments of obstetrics and gynecology. and pathology, O'Connor Hospital, San Jose, Calif.; Reprint requests to 2061 Clamar Way, San Jose. Calif. 95128 (Dr. Whitelaw).

JAMA. 1966;195(9):780-782. doi:10.1001/jama.1966.03100090114032

THE USE OF pure crystalline progesterone which was isolated and prepared for the first time in 1934 was limited mainly in its therapy for the first 13 years to the treatment of habitual and threatened abortion. With the clinical introduction of norethandrolone and norethynodrel in 1956 by Rock'1,2 and his co-workers as contraceptive agents, as well as steroids to increase fertility, there was a rapid increase in the pharmacological use of these products and related steroidal compounds with progestational activity so that today they are being used in the treatment of several gynecological disorders including amenorrhea, oligomenorrhea, dysfunctional bleeding, dysmenorrhea, infertility, contraception, endometriosis, and others,3-7 as well as in the diagnosis of pregnancy. It has been claimed that there are few side reactions of a serious nature, except for fetal virilization,8 persistent edema, and thromboembolic disease.9 We are presenting these data due to the fact that during

First Page Preview View Large
First page PDF preview
First page PDF preview